- Home
- RNXT vs OTLK Comparison
RNXT vs OTLK Comparison
Compare RNXT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- OTLK
- Stock Information
- Founded
- RNXT 2012
- OTLK 2010
- Country
- RNXT United States
- OTLK United States
- Employees
- RNXT N/A
- OTLK N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNXT Health Care
- OTLK Health Care
- Exchange
- RNXT Nasdaq
- OTLK Nasdaq
- Market Cap
- RNXT 43.2M
- OTLK 42.8M
- IPO Year
- RNXT 2021
- OTLK 2016
- Fundamental
- Price
- RNXT $1.11
- OTLK $1.24
- Analyst Decision
- RNXT Strong Buy
- OTLK Buy
- Analyst Count
- RNXT 2
- OTLK 5
- Target Price
- RNXT $7.50
- OTLK $5.25
- AVG Volume (30 Days)
- RNXT 851.9K
- OTLK 2.7M
- Earning Date
- RNXT 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- RNXT N/A
- OTLK N/A
- EPS Growth
- RNXT N/A
- OTLK N/A
- EPS
- RNXT N/A
- OTLK N/A
- Revenue
- RNXT $662,000.00
- OTLK $1,505,322.00
- Revenue This Year
- RNXT $2,895.35
- OTLK N/A
- Revenue Next Year
- RNXT $313.04
- OTLK $343.94
- P/E Ratio
- RNXT N/A
- OTLK N/A
- Revenue Growth
- RNXT N/A
- OTLK N/A
- 52 Week Low
- RNXT $0.75
- OTLK $0.79
- 52 Week High
- RNXT $1.69
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- RNXT 42.40
- OTLK 53.18
- Support Level
- RNXT $1.24
- OTLK $1.04
- Resistance Level
- RNXT $1.42
- OTLK $1.13
- Average True Range (ATR)
- RNXT 0.10
- OTLK 0.07
- MACD
- RNXT -0.01
- OTLK 0.06
- Stochastic Oscillator
- RNXT 11.08
- OTLK 85.22
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.